

# **Australian Government**

### **Department of Health**

# Therapeutic Goods Administration

#### **Public Summary**

Summary for ARTG Entry: 201419 METAGENICS STRESSAN

ARTG entry for Medicine Listed

Sponsor Metagenics (Aust) Pty Ltd

Postal Address PO Box 675, VIRGINIA BC, QLD, 4014

Australia

ARTG Start Date 27/09/2012

Product Category Medicine

Status Active

Approval Area Listed Medicines

#### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

## Products

## 1. METAGENICS STRESSAN

Product Type Single Medicine Product Effective Date 10/12/2019

#### **Permitted Indications**

Traditionally used in Chinese medicine to support healthy stress response in the body

Traditionally used in Chinese medicine to relieve irritability

Traditionally used in Chinese medicine to calms the mind

Traditionally used in Chinese medicine to aid/assist/helps mind relaxation

Traditionally used in Chinese medicine to calm/soothe/nourish/balance spirit

Traditionally used in Chinese medicine to soothe/calm nerves

Traditionally used in Chinese medicine to calmative/nervous system relaxant

### **Indication Requirements**

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

If TCM terminology is used on medicine label, label statement: Talk to a TCM practitioner/health professional if you are unsure if this medicine is right for you.

Label statement: If symptoms persist, talk to your health professional.

#### **Standard Indications**

No Standard Indications included on Record

## **Specific Indications**

No Specific Indications included on Record

#### Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

#### Page 1 of 2

### Produced at 31.08.2021 at 04:37:49 AEST



## **Australian Government**

## **Department of Health**

## Therapeutic Goods Administration

## **Additional Product information**

Pack Size/Poison information	
Pack Size	Poison Schedule

### Components

#### 1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

#### **Active Ingredients**

Bupleurum falcatum root Extract dry concentrate	83.4 mg
Equivalent: Bupleurum falcatum (Dry)	834 mg
Cinnamomum cassia twig Extract dry concentrate	50 mg
Equivalent: Cinnamomum cassia (Dry)	500 mg
hydroxyapatite	46 mg
Panax ginseng root and rhizome Extract dry concentrate	41.7 mg
Equivalent: Panax ginseng (Dry)	417 mg
Pinellia ternata rhizome Extract dry concentrate	66.7 mg
Equivalent: Pinellia ternata (Dry)	667 mg
Scutellaria baicalensis root Extract dry concentrate	41.7 mg
Equivalent: Scutellaria baicalensis (Dry)	417 mg
Uncaria rhyncophylla stem Extract dry concentrate	66 mg
Equivalent: Uncaria rhyncophylla (Dry)	660 mg
Wolfiporia cocos fruiting body Extract dry concentrate	50 mg
Equivalent: Wolfiporia cocos (Dry)	500 mg
Zingiber officinale rhizome Extract dry concentrate	16.7 mg
Equivalent: Zingiber officinale (Fresh)	167 mg
Ziziphus jujuba fruit Extract dry concentrate	41.8 mg
Equivalent: Ziziphus jujuba (Dry)	418 mg
Other In was dispute (Faccini ante)	

### Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate

colloidal anhydrous silica

disodium edetate

gellan gum

hypromellose

magnesium stearate

potable water

potassium acetate

<sup>©</sup> Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.